PipelineReview.com10h
Sapience Therapeutics Enrolls First Patient in Phase 2 Study of ST316, a First-in-Class β-catenin Antagonist, in Colorectal Cancer
TARRYTOWN, NY, USA I October 1, 2024 I Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and ...
PipelineReview.com10h
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
WARREN, NJ, USA I October 1, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of ...
PipelineReview.com10h
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
OXFORD, UK I October 01, 2024 I Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic ...
PipelineReview.com10h
CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions
Collaboration combines BioMarin’s expertise in drug development with CAMP4’s platform-based target discovery capabilities ...
PipelineReview.com9h
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
CAMBRIDGE, MA, USA I September 30, 2024 I Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 ...